- Home
- RUBI vs QLGN Comparison
RUBI vs QLGN Comparison
Compare RUBI & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUBI
- QLGN
- Stock Information
- Founded
- RUBI N/A
- QLGN 1996
- Country
- RUBI Marshall Islands
- QLGN United States
- Employees
- RUBI N/A
- QLGN N/A
- Industry
- RUBI Marine Transportation
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- RUBI Consumer Discretionary
- QLGN Health Care
- Exchange
- RUBI Nasdaq
- QLGN Nasdaq
- Market Cap
- RUBI 8.9M
- QLGN 7.4M
- IPO Year
- RUBI N/A
- QLGN N/A
- Fundamental
- Price
- RUBI $1.58
- QLGN $2.75
- Analyst Decision
- RUBI
- QLGN
- Analyst Count
- RUBI 0
- QLGN 0
- Target Price
- RUBI N/A
- QLGN N/A
- AVG Volume (30 Days)
- RUBI 47.3K
- QLGN 3.7M
- Earning Date
- RUBI 05-06-2020
- QLGN 11-13-2025
- Dividend Yield
- RUBI N/A
- QLGN N/A
- EPS Growth
- RUBI N/A
- QLGN N/A
- EPS
- RUBI N/A
- QLGN N/A
- Revenue
- RUBI $24,139,000.00
- QLGN N/A
- Revenue This Year
- RUBI N/A
- QLGN N/A
- Revenue Next Year
- RUBI N/A
- QLGN N/A
- P/E Ratio
- RUBI $0.80
- QLGN N/A
- Revenue Growth
- RUBI N/A
- QLGN N/A
- 52 Week Low
- RUBI $1.62
- QLGN $1.61
- 52 Week High
- RUBI $6.69
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- RUBI N/A
- QLGN 40.62
- Support Level
- RUBI N/A
- QLGN $2.90
- Resistance Level
- RUBI N/A
- QLGN $5.97
- Average True Range (ATR)
- RUBI 0.00
- QLGN 0.54
- MACD
- RUBI 0.00
- QLGN -0.20
- Stochastic Oscillator
- RUBI 0.00
- QLGN 5.21
About RUBI Rubico Inc. Common Stock
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.